Core Viewpoint - Mirum Pharmaceuticals Inc. is viewed positively by Wall Street analysts, with recent upgrades in price targets following its acquisition of Bluejay Therapeutics for $620 million, which enhances its position in the rare liver disease market [1][2][4]. Group 1: Acquisition Details - Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics for $620 million in cash, gaining worldwide rights to brelovitug, a monoclonal antibody in development for chronic hepatitis D [2][3]. - The acquisition aligns with Mirum's strategy of advancing high-impact medicines for rare diseases, as stated by CEO Chris Peetz [3]. Group 2: Analyst Ratings and Projections - Baird has raised its price target for Mirum Pharmaceuticals from $80 to $88, maintaining an Outperform rating [1][2]. - Morgan Stanley has reiterated an Overweight rating with a price target of $81, viewing the acquisition as a strategic move that could lead to over $4 billion in peak sales from the enlarged pipeline [4]. Group 3: Company Focus - Mirum Pharmaceuticals specializes in developing treatments for rare and debilitating liver diseases, particularly those affecting children, with key products like LIVMARLI for cholestatic pruritus in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis [5].